Skip to main
SEPN
SEPN logo

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc's innovative approach to GPCR oral small molecule drug discovery, powered by its proprietary Native Complex Platform, positions the company well within the rapidly expanding biotechnology market. The anticipated Phase 1 results for SEP-786 and other pipeline candidates in mid-2025 are expected to be significant catalysts, with initial projections estimating around $1.5 billion in annual sales from the CSU indication alone, reflecting the potential of oral therapeutics in a competitive landscape often dominated by injectable formulations. Furthermore, early feedback from specialists indicates positive sentiment towards the launches of SEP-786 and Yorvipath, suggesting a solid foundation for de-risking future development and enhancing pricing flexibility for these treatments.

Bears say

Septerna Inc faces substantial challenges as evident from the unimpressive outcomes of its clinical trials, specifically a Phase 2a trial where serum calcium levels only reached approximately 8 mg/dL, reflecting a less than 50% mean reduction, which raises concerns about the efficacy of its drug candidates. The prevalence of over 50% of non-olfactory GPCR targets being classified as "undruggable" suggests significant limitations in the current technological capabilities, potentially hindering the company's long-term drug discovery efforts. Additionally, the discontinuation of Natpara commercialization by Takeda highlights a broader issue regarding the commercial viability of similar drug candidates in the market, which could adversely impact Septerna's competitive positioning and financial prospects.

Septerna Inc (SEPN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.